Retatrutide: Triple-Receptor Agonism and the Phase 2 Evidence
Retatrutide (LY3437943) is an investigational peptide engineered to activate GIP, GLP-1 and glucagon receptors. This combination is being studied as a way to coordinate appetite, glucose regulation and energy expenditure.Biological context and mechanismGIP and GLP-1 signalling can support…